The 2022 Tandem Meetings | autoHSCT as the best predictor for long-term survival in multiple myeloma
Guillermo José Ruiz-Argüelles, MD, FRCP, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico, talks on the use of autologous hematopoietic stem cell transplantation (autoHSCT) to predict long-term survival in patients with multiple myeloma. A recent study conducted in Mexico demonstrated that autoHSCT was the best determinant of long-term survival irrespective of other characteristics of the disease. In addition, Prof. Ruiz-Argüelles explains that Latin American patients with multiple myeloma have a better prognosis than other populations. According to Prof. Ruiz-Argüelles, autoHSCT is the best available treatment for multiple myeloma. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
